Alcon closed at $77.31 on Nov 4, up 6.83%, 11.3% below its 52-week closing high. Volume of 3.7M shares was 2.29× its 20-day average (well above normal).
Split-adjusted performance: +22.3% over one month, +18.2% over six months, +4.6% over one year.
Short interest was 19.6M shares at the Oct 15 settlement, up 9.4% from the prior report (10.9 days to cover).
No reported quarters with price history yet.
Not enough peers to rank
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
